PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR

PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA  FOR POTENTIAL
USE IN ACTIVE CROHN'S DISEASE 
LUND, SWEDEN -- (Marketwire) -- 10/22/12 --  
Newly Presented Data at 20(th) United European Gastroenterology
(UEG) Week
 Conference Show Significant Impact of Laquinimod on
Clinical Remission versus 
Placebo 
Jerusalem,  Israel  and  Lund,  Sweden,  October  22, 2012 - Teva
Pharmaceutical
Industries  Ltd. (NASDAQ: TEVA) and  Active Biotech 
(NASDAQ OMX  NORDIC: ACTI) today  announced the presentation of Phase
IIa clinical data for investigational
laquinimod in moderate to
severe Crohn's disease (CD). The findings demonstrated
that 
treatment  with  orally  administered  laquinimod 0.5 mg/day resulted
in a robust,  early and consistent effect on  remission (48.3% vs.
15.9% of patients,
respectively)  and response rates (62.1% vs. 34.9%
of patients, respectively) in patients with moderate-to-severe CD
versus placebo. The data were reported in an oral  presentation  at 
the  20(th) United  European Gastroenterology (UEG) Week
conference 
The full abstract can be found at: 
https://uegw.congress-online.com/guest/ID6256b0a50b0e1f/AbstractView?ABSID=1088. 
"Our   developmental   program   for   laquinimod   has  demonstrated
 that the
immunomodulatory  effects  of  this  oral  compound  stand 
to apply to multiple
autoimmune  diseases, and data presented at  UEG
 showed an impressive impact on clinical  remission in Crohn's
disease as early  as one week of treatment," said
Dr.  Michael
Hayden,  President of  Global R&D  and Chief Scientific Officer for
Teva  Pharmaceutical Industries, Ltd. "These data  provide a solid
rationale for potential future study of laquinimod in Crohn's
disease." 
The  Phase  IIa  study  evaluated  the  safety  and efficacy of
various doses of laquinimod  (0.5, 1, 1.5, or  2 mg/day) compared  to
placebo  in active  CD over
eight  weeks of treatment with  four
weeks of follow  up. No effect was noted on remission/response  at
higher  doses. Additionally,  laquinimod 0.5 mg  and 1 mg doses  were
generally well-tolerated, with adverse  events similar to those
seen
with  placebo. The data are currently undergoing further
analysis and evaluation
to finalize next steps in the CD clinical
development plan. 
ABOUT THE STUDY 
The  Phase IIa, multicenter,  randomized, double-blind,
placebo-controlled trial
was  designed to evaluate the safety  and
efficacy of laquinimod in 180 patients
with  moderate  to  severe 
active  CD,  based  on a CD Activity Index (CDAI) of 220-450 and  
serum  C-reactive  protein  (CRP)  levels  of  >5mg/L  or
mucosal
ulcerations  evident on a recent endoscopy.  The study
tracked four dose cohorts
who  received laquinimod 0.5 mg/day, 1
mg/day,  1.5 mg/day, 2 mg/day, or placebo
for  eight  weeks  with 
four  weeks  follow-up.  Approximately 45 patients were
enrolled  in
each cohort  in a 2:1 ration  between laquinimod and
placebo.Stable
concomitant  therapies  and  prior  anti-tumor 
necrosis  factor (TNF) use among
patients was permitted in the study. 
ABOUT LAQUINIMOD 
Laquinimod  is a novel  oral immunomodulator under  clinical
development for the treatment  of multiple sclerosis  (MS), Crohn's
disease  (CD) and systemic lupus
erythematosus  (SLE or lupus). Human
and animal models suggest laquinimod exerts
its  therapeutic effect
by modulating the  immune system cells, mainly resulting
in a down
regulation of pro-inflammatory cytokines. 
ABOUT CROHN'S DISEASE 
CD  is a chronic inflammatory condition that affects the
gastrointestinal tract.
The  symptoms of CD can vary significantly
among afflicted individuals. The main
gastrointestinal  symptoms are
abdominal pain, diarrhea,  or weight loss. CD can also  cause
complications  outside of  the gastrointestinal  tract such  as
skin
rashes, arthritis, and inflammation of the eye. The  precise
cause  of CD  is not  known. CD  is considered  to be an
autoimmune
disease.  This autoimmune activity produces inflammation
in the gastrointestinal
tract. CD is classified as an inflammatory
bowel disease, IBD. 
ABOUT TEVA 
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading
global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing
affordable generic drugs as
well as innovative and specialty
pharmaceuticals and active pharmaceutical ingredients. Headquartered
in Israel, Teva is the world's largest generic drug
maker, with a
global product portfolio of more than 1,300 molecules and a
direct
presence in about 60 countries. Teva's branded businesses
focus on CNS, oncology, pain, respiratory and women's health
therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world
and reached $18.3
billion in net revenues in 2011. 
ABOUT ACTIVE BIOTECH 
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with focus on autoimmune/inflammatory diseases and cancer.
Projects in or entering
pivotal phase are laquinimod, an orally
administered small molecule with unique
immunomodulatory properties
for the treatment of multiple sclerosis, TASQ for
prostate cancer as
well as ANYARA for use in cancer targeted therapy, primarily
of renal
cell cancer. In addition, laquinimod is in Phase II development
for
Crohn's and Lupus. Further projects in clinical development
comprise the two
orally administered compounds, 57-57 for SLE &
Systemic Sclerosis and RhuDex(TM)
for RA. Please visit
http://www.activebiotech.com for more information. 
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995: 
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management's current beliefs and expectations and involve a
number of known and
unknown risks and uncertainties that could cause
our future results, performance
or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Important
factors that
could cause or contribute to such differences include risks relating
to: our ability to successfully develop and commercialize
additional
pharmaceutical products, the introduction of competing
generic equivalents, the
extent to which we may obtain U.S. market
exclusivity for certain of our new
generic products and regulatory
changes that may prevent us from utilizing exclusivity periods,
potential liability for sales of generic products prior to a final
resolution of outstanding patent litigation, including that relating
to the generic version of Protonix(R), the extent to which any
manufacturing or
quality control problems damage our reputation for
high quality production, the
effects of competition on sales of our
innovative products, especially Copaxone(R) (including potential
generic and oral competition for Copaxone(R)),
the impact of
continuing consolidation of our distributors and customers,
our
ability to identify, consummate and successfully integrate
acquisitions (including the acquisition of Cephalon), interruptions in
our supply chain or
problems with our information technology systems
that adversely affect our complex manufacturing processes, intense
competition in our specialty pharmaceutical businesses, any failures
to comply with the complex Medicare and
Medicaid reporting and
payment obligations, our exposure to currency fluctuations and
restrictions as well as credit risks, the effects of reforms in
healthcare regulation, adverse effects of political or economical
instability,
major hostilities or acts of terrorism on our
significant worldwide operations,
increased government scrutiny in
both the U.S. and Europe of our agreements with
brand companies,
dependence on the effectiveness of our patents and other protections
for innovative products, our ability to achieve expected
results
through our innovative R&D efforts, the difficulty of
predicting U.S. Food and
Drug Administration, European Medicines
Agency and other regulatory authority
approvals, uncertainties
surrounding the legislative and regulatory pathway for
the
registration and approval of biotechnology-based products,
potentially significant impairments of intangible assets and goodwill,
potential increases
in tax liabilities resulting from challenges to
our intercompany arrangements,
our potential exposure to product
liability claims to the extent not covered by insurance, the
termination or expiration of governmental programs or tax benefits,
current economic conditions, any failure to retain key personnel or
to attract additional executive and managerial talent, environmental
risks and other factors that are discussed in our Annual Report on
Form 20-F and other
filings with the U.S. Securities and Exchange
Commission. 
Active Biotech's Safe Harbor Statement in Accordance with the Swedish
Securities
Market Act: 
This press release contains certain forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause the actual
results, performance or achievements of the company, or industry
results, to differ materially from any
future results, performance or
achievement implied by the forward-looking statements. The company
does not undertake any obligation to update or publicly
release any
revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press
release. 
Active Biotech is obligated to publish the information contained in
this press
release in accordance with the Swedish Securities Market
Act. This information
was provided to the media for publication 3:00
p.m. CET on October 22, 2012. 
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA :
http://hugin.info/1002/R/1651043/532562.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE [HUG#1651043] 
IR Contacts:
Kevin C. Mannix
United States
(215) 591-8912 
Joseph Marczely
United States
(267) 468-4281 
Tomer Amitai
Israel
972 (3) 926-7656 
PR Contacts
Hadar Vismunski-Weinberg
Israel
972 (3) 926-7687 
Denise Bradley
United States
(215) 591-8974 
Active Biotech
Tomas Leanderson
Active Biotech AB
46-19-20-95 
Hans Kolam
Active Biotech AB
46-19-20-44
 
 
Press spacebar to pause and continue. Press esc to stop.